Usa covid-19 experts vaccine Usa

J&J booster up to 94% effective against severe COVID, company says

Reading now: 342
www.cidrap.umn.edu

Today, Johnson & Johnson (J&J) announced that a second dose of its COVID-19 vaccine given 2 months after the first raises its effectiveness against moderate to severe disease from 70% to 94% in the United States.

The booster was also well tolerated, generating side effects similar to those observed after the first dose.Promising data, but some experts want moreIn a press release, the company said that its phase 3 US clinical trial data showed that a booster dose given at 56 days conferred 94% protection against moderate to severe disease in nearly 30,000 adult participants.

The confidence interval (CI), however, was wide, at 58% to 100%, leaving doubt as to the precision of the finding.J&J also said that antibody levels quadrupled when a

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA